---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-002741"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:52:38.030599+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics reports cash $90.3M; Phase 3 uproleselan data still after 2022

## Summary
- Cash and equivalents $90.3M at Dec 31, 2021 vs $137.0M at Dec 31, 2020; revenue fell to $1.2M from $10.2M.
- Pivotal Phase 3 uproleselan trial in relapsed/refractory AML completed enrollment (388 patients); top-line data expected after year-end 2022.
- NCI Phase 2/3 registration trial (newly diagnosed AML) completed Phase 2 enrollment (267 patients); interim analysis planned.
- Apollomics initiated Phase 3 uproleselan trial in Greater China in November 2021 after Breakthrough Therapy designation.
- Expanded executive team: hired Lisa DeLuca (VP Regulatory), Bruce Johnson (SVP/Chief Commercial Officer), Deepak Tiwari (VP Technical Operations).

## SEC filing metadata
- accession: 0001558370-22-002741
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837022002741/0001558370-22-002741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837022002741/glyc-20220303x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-002741
- JSON: https://secwatch.observer/filing/0001558370-22-002741.json
- Plain text: https://secwatch.observer/filing/0001558370-22-002741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.